These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16922589)

  • 1. Current efforts on generation of optimal immune responses against HIV through mucosal immunisations.
    Vajdy M
    Drugs R D; 2006; 7(5):267-88. PubMed ID: 16922589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal delivery of vaccines against HIV.
    Vajdy M; Singh M
    Expert Opin Drug Deliv; 2006 Mar; 3(2):247-59. PubMed ID: 16506951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.
    Yu M; Vajdy M
    Expert Opin Biol Ther; 2010 Aug; 10(8):1181-95. PubMed ID: 20624114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal HIV vaccines: where are we now?
    Stevceva L; Strober W
    Curr HIV Res; 2004 Jan; 2(1):1-10. PubMed ID: 15053336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal AIDS vaccines: current status and future directions.
    Belyakov IM; Ahlers JD; Berzofsky JA
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S65-73. PubMed ID: 15285706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses.
    McKay PF; Mann JF; Pattani A; Kett V; Aldon Y; King D; Malcolm RK; Shattock RJ
    J Control Release; 2017 Mar; 249():74-83. PubMed ID: 28115243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines.
    Belyakov IM; Berzofsky JA
    Immunity; 2004 Mar; 20(3):247-53. PubMed ID: 15030769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.
    Belyakov IM; Ahlers JD
    Curr Top Microbiol Immunol; 2012; 354():157-79. PubMed ID: 21203884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate and adaptive mucosal immunity in protection against HIV infection.
    Lehner T
    Vaccine; 2003 Jun; 21 Suppl 2():S68-76. PubMed ID: 12763686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery systems and adjuvants for vaccination against HIV.
    Velin D; Kraehenbuhl JP
    EXS; 2000; 89():227-37. PubMed ID: 10997292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in HIV vaccines inducing mucosal immune responses.
    Pavot V; Rochereau N; Lawrence P; Girard MP; Genin C; Verrier B; Paul S
    AIDS; 2014 Jul; 28(12):1701-18. PubMed ID: 25009956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
    Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
    Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
    Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
    J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of optimal immune responses against human immunodeficiency virus at mucosal portals of entry.
    Vajdy M
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):222-33. PubMed ID: 12871029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery systems and adjuvants for vaccination against HIV.
    Velin D; Hopkins S; Kraehenbuhl J
    Pathobiology; 1998; 66(3-4):170-5. PubMed ID: 9693320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of mucosal immunity in prevention of HIV transmission.
    Kozlowski PA; Neutra MR
    Curr Mol Med; 2003 May; 3(3):217-28. PubMed ID: 12699359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.
    Ranasinghe C; Medveczky JC; Woltring D; Gao K; Thomson S; Coupar BE; Boyle DB; Ramsay AJ; Ramshaw IA
    Vaccine; 2006 Jul; 24(31-32):5881-95. PubMed ID: 16759767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.